Novo Nordisk once-weekly insulin clears first phase 3 test

For many patients with type 2 diabetes, having to inject basal insulin every day is a burdensome fact of life, but Novo Nordisk is trying to change that.

FDA sets August decision date for Provention's type 1 diabet...

Shares in Provention Bio cratered last July when the FDA turned down its marketing application for type 1 diabetes therapy teplizumab.

Merck makes another bioelectronics play, partnering with Inn...

Merck KGaA has forged a second partnership in the bioelectronics category in two weeks, teaming up with Innervia to develop neurostimulator devices for treating chronic diseases.

FDA rejects Provention's type 1 diabetes drug teplizumab

The FDA indicated something was not well with Provention Bio's filing for type 1 diabetes therapy teplizumab in April when it delayed its review.

Provention faces delay in FDA review of diabetes prevention ...

The FDA says it has uncovered "deficiencies" in the marketing application for Provention Bio's much-anticipated drug teplizumab for the prevention of

Lilly, Boehringer bag FDA okay for diabetes triple Trijardy ...